. 2011 Oct 18;3(1):134–140. doi: 10.3892/etm.2011.368

Table III.

Summary of quality of life (QOL) scales^a in selected trials (12–17 weeks).

Authors/(Refs.)	Data	Treatment	Patients (no.)	Global QOL	Fatigue	Nausea and vomiting	Pain	Dyspnoea	Insomnia	Appetite loss	Constipation
Rosell et al (21)	p-value	CDDP	171	0.939	0.955	0.149	0.058	0.163	0.985	0.084	0.468
Rosell et al (21)	p-value	CBDCA	172
Scagliotti et al (22)	Mean change from baseline^b	CDDP	132	-	5	11	-	-	-	−1	-
Scagliotti et al (22)	Mean change from baseline^b	CBDCA	99	-	10	4				2	-
Danson et al (23)	Percentage change from baseline^b	CDDP	50	50%^d	70%^d	48%^d	36%^c	40%^c	20%^d	19%^d	21%^d
Danson et al (23)	Percentage change from baseline^b	CBDCA	54	40%^d	49%^d	28%^d	46%^c	25%^c	35%^d	39%^d	2%^d
Paccagnella et al (24)	p-value	CDDP	39	0.40	0.15	<0.001	0.47	0.17	0.03	0.01	0.01
Paccagnella et al (24)	p-value	CBDCA	38
Rudd et al (25)	Median change from baseline (interquartile range)	CDDP	120	0	0.33	0	0	0	0	0	0
				(−1.0–0.50)	(−0.33–0.67)	(0–0.50)	(−0.50–0))	(0–0)	(−1.0–0)	(−1.0–0)	(0–0)
		CBDCA	112	0	0	0	0	0	0	0	0
				(−1.0–1.0)	(−0.33–0.67)	(0–0)	(−0.50–0)	(−1.0–0)	(−1.0–1.0)	(−1.0–0)	(0–0)
Booton et al (26)	Median change from baseline (interquartile range)	CDDP	22	0	11	0	0	0	−33	0	0
Booton et al (26)	Median change from baseline (interquartile range)	CBDCA	26	0	11	0	0	0	0	0	0

QOL scales, a higher score indicates a better global QOL and a greater severity of symptoms (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation);

value that was shown on a chart;

improvement;

deterioration. CDDP, cisplatin; CBDCA, carboplatin.